BioAtla (BCAB) to Release Earnings on Thursday

BioAtla (NASDAQ:BCAB) is expected to be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect BioAtla to post earnings of ($0.31) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, November 13, 2025 at 4:30 PM ET.

BioAtla (NASDAQ:BCAB) last posted its earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). On average, analysts expect BioAtla to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioAtla Stock Down 5.0%

Shares of BioAtla stock opened at $0.66 on Tuesday. BioAtla has a 12-month low of $0.24 and a 12-month high of $2.53. The stock has a 50 day moving average price of $0.68 and a two-hundred day moving average price of $0.50. The stock has a market capitalization of $39.01 million, a P/E ratio of -0.60 and a beta of 1.03.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BioAtla stock. Acadian Asset Management LLC grew its stake in BioAtla, Inc. (NASDAQ:BCAB) by 968.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,690,110 shares of the company’s stock after purchasing an additional 1,531,994 shares during the period. Acadian Asset Management LLC owned approximately 2.89% of BioAtla worth $585,000 as of its most recent filing with the Securities and Exchange Commission. 77.23% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BCAB. Citizens Jmp downgraded BioAtla from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAtla in a report on Tuesday, October 14th. JMP Securities reiterated a “market perform” rating on shares of BioAtla in a research note on Wednesday, August 13th. Finally, Wall Street Zen raised BioAtla to a “sell” rating in a research report on Saturday, September 6th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Reduce”.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.